News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Biogen (BIIB)'s New CEO Stands To Gain From An Acquisition



12/22/2016 7:26:51 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Biogen’s announcement Monday that chief commercial officer Michel Vounatsos will take over as CEO has rekindled a debate over whether the Cambridge biotech could be acquired in its current, precarious state.

But at least one thing is clear: Vounatsos stands to personally benefit if Biogen (Nasdaq: BIIB) is purchased.

A look at Vounatsos' employment agreement, which was posted in a regulatory filing late Monday, shows that Biogen is giving its new chief generous protections in the event of a “change of control” — corporate-speak for an acquisition.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES